Company intelligence / Profile preview

Quantro Therapeutics

Ownership: Private
Development stage: Other

Overview

Quantro Therapeutics has achieved a breakthrough in multiplexed target screening using its proprietary transcriptomic drug discovery platform. The company has validated hits and demonstrated on-target activity for multiple molecular targets in oncology and inflammation. No clinical results have been published yet; the pipeline remains preclinical with a focus on first-in-class therapies against previously undruggable transcription factors.

Therapeutic areas: ImmunologyOncologyOther
Modalities: Small moleculeMolecular glue therapyPeptidesRNA therapy
Industry: Biotech

Partnerships

Evotec SEBoehringer Ingelheim Venture Fund

Beyond the preview

Go deeper on Quantro Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quantro Therapeutics.

Explore the full profile